Importantly, the PDTF platform can be also applied to identify suitable neoadjuvant treatment strategies in patients with early-stage cancer, as recently described for anti-CTLA-4 plus anti-PD-1 combined with IL-2 in PDE of checkpoint inhibitor-resistant melanoma patients (25). Here, PDCD1 is linked to cancer.